SGN228-001: A phase I open-label dose-escalation, and expansion study of SGN-CD228A in select advanced solid tumors.

医学 转移性乳腺癌 耐受性 实体瘤疗效评价标准 人源化抗体 肿瘤科 癌症 放射免疫疗法 癌症研究 抗体-药物偶联物 内科学 乳腺癌 临床研究阶段 抗体 不利影响 单克隆抗体 化疗 免疫学
作者
Amita Patnaik,Funda Meric‐Bernstam,Caio Max Sao Pedro Rocha Lima,Francisco Robert,Afshin Dowlati,Hedy L. Kindler,Diwakar Davar,Steven Powell,Phillip M. Garfin,Ani Sarkis Balmanoukian
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:38 (15_suppl): TPS3652-TPS3652 被引量:7
标识
DOI:10.1200/jco.2020.38.15_suppl.tps3652
摘要

TPS3652 Background: SGN-CD228A is an investigational antibody-drug conjugate (ADC) that targets CD228, a cell-surface oncofetal protein with prevalent expression in several types of cancer and limited expression on normal tissues. SGN-CD228A consists of a humanized IgG1 anti-CD228 monoclonal antibody conjugated to an average of 8 molecules of monomethyl auristatin E (MMAE) via a PEGylated β-glucuronidase cleavable linker. MMAE is a well-studied and highly active chemotype with an established safety profile. The proposed mechanism of action involves binding CD228 on cell surfaces, ADC internalization, and trafficking to lysosomes. MMAE is then released through β-glucuronidase cleavage of the glucuronide MMAE linker. MMAE then binds tubulin, which disrupts microtubule networks and causes cell cycle arrest and apoptosis. Methods: SGN228-001 (NCT04042480) is a phase 1, open label, multicenter, dose escalation, and expansion study enrolling up to 240 subjects to evaluate the safety, tolerability, PK, and antitumor activity of SGN-CD228A in select advanced solid tumors. Eligible subjects are ≥18 years of age and have metastatic cutaneous melanoma, malignant pleural mesothelioma, human epidermal growth factor receptor 2-negative metastatic breast cancer, advanced non-small cell lung cancer, metastatic colorectal cancer, or advanced pancreatic ductal adenocarcinoma. Subjects must have relapsed, refractory, or progressive disease, and should have no appropriate standard therapy available. Measurable disease per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), Eastern Cooperative Oncology Group (ECOG) performance status score of ≤1, and adequate renal, hepatic, and hematologic function are required. The study includes dose escalation and dose expansion, with multiple disease-specific dose expansion cohorts and a biology cohort. Dose escalation will be conducted using the modified toxicity probability interval method (Ji 2010) to evaluate the safety and identify the maximum tolerated dose of SGN-CD228A. Following dose escalation, disease-specific expansion cohorts and a biology cohort (to evaluate exploratory biomarkers) are planned. Response assessments will be conducted every 6 weeks per RECIST v1.1 and all subjects will be followed for safety. Pharmacokinetics and markers of pharmacodynamics will be assessed regularly. Key efficacy endpoints include objective response rate, progression-free survival, and duration of objective response. Enrollment is ongoing in the US and planned in Europe. Clinical trial information: NCT04042480 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
LI发布了新的文献求助10
刚刚
yanchen发布了新的文献求助10
刚刚
qiang344完成签到 ,获得积分10
刚刚
Orange的应助被啵子采纳,获得10
1秒前
lee123完成签到,获得积分10
1秒前
yansiyi发布了新的文献求助20
2秒前
Xk发布了新的文献求助10
2秒前
聪慧凡蕾完成签到,获得积分10
2秒前
2秒前
5秒前
5秒前
5秒前
拓跋幻枫完成签到,获得积分10
7秒前
777发布了新的文献求助10
7秒前
chen01hang的应助被可靠老头采纳,获得10
8秒前
8秒前
科研通AI6.3的应助被zyy采纳,获得10
8秒前
daomaihu发布了新的文献求助100
9秒前
9秒前
young完成签到,获得积分10
9秒前
好巧完成签到,获得积分10
10秒前
11秒前
11秒前
11秒前
1111发布了新的文献求助10
11秒前
研友_VZG7GZ的应助被鲤鱼鑫磊采纳,获得10
12秒前
林见鹿发布了新的文献求助10
12秒前
荀彧发布了新的文献求助10
12秒前
Xk发布了新的文献求助10
12秒前
13秒前
小二郎的应助被风吹麦浪采纳,获得10
13秒前
田様的应助被风吹麦浪采纳,获得10
13秒前
心心发布了新的文献求助10
14秒前
14秒前
15秒前
Bonnie完成签到,获得积分10
15秒前
wooo发布了新的文献求助10
15秒前
ubless607发布了新的文献求助30
16秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187362
求助须知:如何正确求助?哪些是违规求助? 9575478
关于积分的说明 21841431
捐赠科研通 7785067
什么是DOI,文献DOI怎么找? 3434943
关于科研通互助平台的介绍 2559401
邀请新用户注册赠送积分活动 2481820